1. Home
  2. HCVI vs PBYI Comparison

HCVI vs PBYI Comparison

Compare HCVI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HCVI
  • PBYI
  • Stock Information
  • Founded
  • HCVI 2021
  • PBYI 2010
  • Country
  • HCVI United States
  • PBYI United States
  • Employees
  • HCVI N/A
  • PBYI N/A
  • Industry
  • HCVI Blank Checks
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • HCVI Finance
  • PBYI Health Care
  • Exchange
  • HCVI Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • HCVI 176.6M
  • PBYI 176.1M
  • IPO Year
  • HCVI 2021
  • PBYI N/A
  • Fundamental
  • Price
  • HCVI $10.68
  • PBYI $2.60
  • Analyst Decision
  • HCVI
  • PBYI Strong Buy
  • Analyst Count
  • HCVI 0
  • PBYI 1
  • Target Price
  • HCVI N/A
  • PBYI $7.00
  • AVG Volume (30 Days)
  • HCVI 52.6K
  • PBYI 347.3K
  • Earning Date
  • HCVI 01-01-0001
  • PBYI 10-31-2024
  • Dividend Yield
  • HCVI N/A
  • PBYI N/A
  • EPS Growth
  • HCVI N/A
  • PBYI N/A
  • EPS
  • HCVI N/A
  • PBYI 0.18
  • Revenue
  • HCVI N/A
  • PBYI $219,143,000.00
  • Revenue This Year
  • HCVI N/A
  • PBYI N/A
  • Revenue Next Year
  • HCVI N/A
  • PBYI N/A
  • P/E Ratio
  • HCVI N/A
  • PBYI $14.17
  • Revenue Growth
  • HCVI N/A
  • PBYI N/A
  • 52 Week Low
  • HCVI $10.30
  • PBYI $2.13
  • 52 Week High
  • HCVI $11.47
  • PBYI $7.73
  • Technical
  • Relative Strength Index (RSI)
  • HCVI 63.86
  • PBYI 46.47
  • Support Level
  • HCVI $10.62
  • PBYI $2.45
  • Resistance Level
  • HCVI $10.66
  • PBYI $2.63
  • Average True Range (ATR)
  • HCVI 0.01
  • PBYI 0.14
  • MACD
  • HCVI 0.00
  • PBYI 0.06
  • Stochastic Oscillator
  • HCVI 100.00
  • PBYI 92.50

About HCVI Hennessy Capital Investment Corp. VI

Hennessy Capital Investment Corp VI is a shell company.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: